FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases
2011

Treatment of Relapsed Follicular Lymphoma with FCR and Radioimmunotherapy

Sample size: 9 publication Evidence: moderate

Author Information

Author(s): Francesco Pisani, Carlo Ludovico Maini, Rosa Sciuto, Laura Dessanti, Mariella D'Andrea, Daniela Assisi, Maria Concetta Petti

Primary Institution: Regina Elena National Cancer Institute

Hypothesis

Is the combination of FCR followed by 90Y-RIT effective for treating relapsed grades 1 and 2 follicular lymphoma?

Conclusion

The study shows that FCR followed by 90Y-RIT is feasible, tolerable, and effective for patients with relapsed grades 1 and 2 follicular lymphoma.

Supporting Evidence

  • Seven patients achieved complete remission after FCR.
  • Two patients converted from partial remission to complete remission after 90Y-RIT.
  • Overall survival rates were 89% at 2 years, 76% at 3 years, and 61% at 4 years.

Takeaway

Doctors treated 9 patients with a specific medicine combination for a type of cancer, and most of them got better.

Methodology

Patients received FCR followed by 90Y-RIT and were monitored for response and side effects.

Potential Biases

Potential bias due to the retrospective nature of the study and lack of a control group.

Limitations

The study is retrospective and includes a small sample size.

Participant Demographics

Median age was 63 years, with a range of 46-77 years; 3 males and 6 females.

Digital Object Identifier (DOI)

10.1186/1756-9966-30-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication